- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | TScan Therapeutics führt Halteprogramm für wichtige Führungskräfte ein | 2 | Investing.com Deutsch | ||
| 11.09. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | H.C. Wainwright downgrades Tscan stock rating on restructuring | 1 | Investing.com | ||
| 02.09. | TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction | 2 | Benzinga.com | ||
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.09. | TScan axes 75% of workforce to make room for solid tumor programs | 1 | FierceBiotech | ||
| 02.09. | Wedbush stuft Tscan Therapeutics nach Strategiewechsel auf 'Neutral' herab | 2 | Investing.com Deutsch | ||
| 02.09. | Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift | 3 | Investing.com | ||
| 02.09. | TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11% | 3 | RTTNews | ||
| 02.09. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors | 299 | GlobeNewswire (Europe) | Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA... ► Artikel lesen | |
| 13.08. | H.C. Wainwright bestätigt Kaufempfehlung für Tscan Therapeutics nach positiven Studiendaten | 1 | Investing.com Deutsch | ||
| 13.08. | H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy | 1 | Investing.com | ||
| 12.08. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | TScan Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.05M misses by $0.83M | 1 | Seeking Alpha | ||
| 12.08. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | TScan Therapeutics, Inc.: TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 473 | GlobeNewswire (Europe) | First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA study, validating internal commercial-ready manufacturing... ► Artikel lesen | |
| 29.07. | TScan verabreicht erstem Patienten Dosis in Phase-3-Studie zu AML und MDS | 2 | Investing.com Deutsch | ||
| 30.06. | TScan Therapeutics auf der H.C. Wainwright Konferenz: Phase-III-Studie für TSC-101 gewinnt an Fahrt | 1 | Investing.com Deutsch | ||
| 22.06. | TScan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation | 460 | GlobeNewswire (Europe) | 11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| REGENERON PHARMACEUTICALS | 685,10 | +0,53 % | Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent | ||
| PALATIN TECHNOLOGIES | 10,900 | +0,37 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,927 | -0,11 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -1,48 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,568 | +0,02 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen |
Das Unternehmen TSCAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,312 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.